AU2007311395B2 - Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides - Google Patents

Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides Download PDF

Info

Publication number
AU2007311395B2
AU2007311395B2 AU2007311395A AU2007311395A AU2007311395B2 AU 2007311395 B2 AU2007311395 B2 AU 2007311395B2 AU 2007311395 A AU2007311395 A AU 2007311395A AU 2007311395 A AU2007311395 A AU 2007311395A AU 2007311395 B2 AU2007311395 B2 AU 2007311395B2
Authority
AU
Australia
Prior art keywords
seq
peptide
cancer
depdc1
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007311395A
Other languages
English (en)
Other versions
AU2007311395A1 (en
Inventor
Tomoaki Fujioka
Yusuke Nakamura
Ryuji Osawa
Midori Shida
Takuya Tsunoda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of AU2007311395A1 publication Critical patent/AU2007311395A1/en
Priority to AU2013200566A priority Critical patent/AU2013200566B2/en
Application granted granted Critical
Publication of AU2007311395B2 publication Critical patent/AU2007311395B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
AU2007311395A 2006-10-17 2007-10-16 Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides Ceased AU2007311395B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013200566A AU2013200566B2 (en) 2006-10-17 2013-02-04 Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85257506P 2006-10-17 2006-10-17
US60/852,575 2006-10-17
PCT/JP2007/001122 WO2008047473A1 (en) 2006-10-17 2007-10-16 Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013200566A Division AU2013200566B2 (en) 2006-10-17 2013-02-04 Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides

Publications (2)

Publication Number Publication Date
AU2007311395A1 AU2007311395A1 (en) 2008-04-24
AU2007311395B2 true AU2007311395B2 (en) 2013-02-21

Family

ID=39313729

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007311395A Ceased AU2007311395B2 (en) 2006-10-17 2007-10-16 Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides

Country Status (17)

Country Link
US (5) US8557955B2 (enExample)
EP (7) EP2687540A1 (enExample)
JP (2) JP5339292B2 (enExample)
KR (4) KR101527473B1 (enExample)
CN (5) CN101568550B (enExample)
AU (1) AU2007311395B2 (enExample)
BR (1) BRPI0717651A2 (enExample)
CA (2) CA2915560A1 (enExample)
DK (1) DK2091965T3 (enExample)
ES (4) ES2545457T3 (enExample)
IL (4) IL198186A (enExample)
MX (1) MX2009004147A (enExample)
PL (1) PL2091965T3 (enExample)
PT (1) PT2091965E (enExample)
RU (1) RU2469044C2 (enExample)
SG (2) SG10201502098YA (enExample)
WO (1) WO2008047473A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5109131B2 (ja) 2005-02-10 2012-12-26 オンコセラピー・サイエンス株式会社 膀胱癌を診断する方法
US8455444B2 (en) * 2007-08-20 2013-06-04 Oncotherapy Science, Inc. CDH3 peptide and medicinal agent comprising the same
EP2362904B1 (en) * 2008-08-28 2016-11-16 Oncotherapy Science, Inc. Method of screening compounds for use in inhibiting depdc1 - znf224 binding
WO2010100878A1 (en) * 2009-03-04 2010-09-10 Oncotherapy Science, Inc. Vangl1 peptides and vaccines including the same
WO2012032763A1 (en) * 2010-09-07 2012-03-15 Oncotherapy Science, Inc. Vangl1 peptides and vaccines including the same
KR102015648B1 (ko) * 2011-08-12 2019-08-28 온코세라피 사이언스 가부시키가이샤 Ｍｐｈｏｓｐｈ１ 펩티드 및 이를 포함한 백신
JP2013058294A (ja) * 2011-09-09 2013-03-28 Toshiba Corp 磁気記録媒体及び磁気記録媒体の製造方法
JP6362543B2 (ja) 2012-02-23 2018-07-25 ジュノ セラピューティクス ゲーエムベーハー 細胞および他の複雑な生物学的材料のクロマトグラフィーによる単離
US20150359864A1 (en) 2012-03-09 2015-12-17 Oncotherapy Science, Inc. Pharmaceutical composition containing peptides
JP6041297B2 (ja) * 2012-08-24 2016-12-07 国立大学法人山口大学 犬リンパ腫の診断方法及び診断キット
CA2904802C (en) * 2013-03-13 2021-03-30 Zhong Li Microvesicle and method for producing the same
LT3132247T (lt) 2014-04-16 2021-12-10 Juno Therapeutics Gmbh Ląstelių populiacijos padauginimo būdai, rinkiniai ir priemonės
US10537626B2 (en) 2014-10-07 2020-01-21 Cytlimic Inc. HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell
EP3207936B1 (en) * 2014-11-18 2021-04-21 Shionogi & Co., Ltd. Stable peptide composition
JP6898225B2 (ja) 2015-03-09 2021-07-07 サイトリミック株式会社 Ｇｐｃ３由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法
EP3797794A1 (en) 2015-04-07 2021-03-31 Cytlimic Inc. Medicine comprising a toll like receptor 3 agonist and a lag-3 protein
AU2016306527B2 (en) * 2015-08-12 2022-03-17 Oncotherapy Science, Inc. DEPDC1-derived peptide and vaccine containing same
HK1251928A1 (en) * 2015-10-08 2019-05-03 Oncotherapy Science, Inc. MPHOSPH1-derived peptides and vaccines including it
US11466253B2 (en) 2015-10-22 2022-10-11 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
CN108474791B (zh) 2015-10-22 2022-07-08 朱诺治疗学有限公司 培养细胞的方法及用于该方法的试剂盒和设备
HK1258932A1 (zh) 2015-10-22 2019-11-22 Juno Therapeutics Gmbh 用於转导的方法、反应剂盒、反应剂和设备
AU2017342189B2 (en) 2016-10-11 2023-09-21 Nec Corporation Medicine
WO2018092755A1 (en) * 2016-11-18 2018-05-24 Oncotherapy Science, Inc. Mphosph1 epitope peptides for th1 cells and vaccines containing the same
JP2019535270A (ja) * 2016-11-18 2019-12-12 オンコセラピー・サイエンス株式会社 Ｔｈ１細胞のためのＤＥＰＤＣ１エピトープペプチドおよびこれを含有するワクチン
WO2018094569A1 (zh) * 2016-11-22 2018-05-31 深圳华大基因研究院 多肽及其应用
MX2019008878A (es) 2017-01-25 2020-02-13 Ose Immunotherapeutics Metodo para fabricar una emulsion estable para suministro de peptidos.
MA49288A (fr) 2017-04-27 2020-03-04 Juno Therapeutics Gmbh Reactifs particulaires oligomères et leurs méthodes d'utilisation
SG11202000250PA (en) * 2017-07-12 2020-02-27 Nouscom Ag A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (msi) cancers
RU2760984C1 (ru) 2017-12-13 2021-12-02 Иновио Фармасьютикалз, Инк. Противораковые вакцины, направленные на lemd1, и их применение
CN109932510B (zh) * 2017-12-18 2022-07-12 天津云检医学检验所有限公司 一种宫颈癌生物标志物及其检测试剂盒
SG11202101204TA (en) 2018-08-09 2021-03-30 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
EP3874024A1 (en) 2018-10-31 2021-09-08 Juno Therapeutics GmbH Methods for selection and stimulation of cells and apparatus for same
CN112142824B (zh) * 2019-06-27 2022-03-11 深圳市东贵博康生化科技有限公司 具有诱导细胞毒性t淋巴细胞能力的多肽及其应用
WO2021060343A1 (ja) * 2019-09-24 2021-04-01 オンコセラピー・サイエンス株式会社 Ｕｒｌｃ１０由来ペプチドまたはｄｅｐｄｃ１由来ペプチドを認識するヒトｔ細胞が発現するｔ細胞受容体
CN116368570A (zh) * 2020-10-15 2023-06-30 米尼奥公司 用于确定肽免疫原性的方法、系统和计算机程序产品

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002046416A2 (en) * 2000-12-04 2002-06-13 Argonex Pharmaceuticals Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2003040165A2 (en) * 2000-10-19 2003-05-15 Epimmune Inc. Hla class i and ii binding peptides and their uses
WO2006085684A2 (en) * 2005-02-10 2006-08-17 Oncotherapy Science, Inc. Method of diagnosing bladder cancer

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
RU94038427A (ru) 1991-08-26 1996-10-20 Сайтел Корпорейшн (US) Пептиды, конъюгаты, фармацевтические композиции, способы лечения, способ идентификации
JP3738395B2 (ja) 1991-08-26 2006-01-25 エピミューン，インコーポレイティド Ｈｌａ−制限型ｂ型肝炎ウィルスのｃｔｌエピトープ
AU678225B2 (en) * 1993-03-11 1997-05-22 University Of Southern California Therapeutic strategies for immunoinfective cluster virus infections
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
CA2225553A1 (en) 1995-08-03 1997-02-20 Rijksuniversiteit Te Leiden Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
WO1998004720A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US7001999B1 (en) * 1998-04-15 2006-02-21 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
PL201881B1 (pl) * 1998-09-30 2009-05-29 Corixa Corp Izolowany polipeptyd składający się z immunogennej części natywnego WT1, zawierająca go kompozycja farmaceutyczna i szczepionka oraz polinukleotyd kodujący ten polipeptyd
US20050123938A1 (en) 1999-01-06 2005-06-09 Chondrogene Limited Method for the detection of osteoarthritis related gene transcripts in blood
US20040241726A1 (en) * 1999-01-06 2004-12-02 Chondrogene Limited Method for the detection of allergies related gene transcripts in blood
US6291663B1 (en) * 1999-03-03 2001-09-18 Board Of Trustees Of The University Of Arkansas TADG-12: a novel transmembrane serine protease overexpressed in a ovarian carcinoma
US7030215B2 (en) * 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
JP2003518364A (ja) * 1999-05-28 2003-06-10 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 乳癌、胃癌および前立腺癌関連抗原ならびにそれらの使用
CA2420543C (en) 2000-08-22 2013-04-02 Agensys, Inc. Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
AU2001296235A1 (en) 2000-10-12 2002-04-22 Hyseq, Inc. Novel nucleic acids and polypeptides
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
JP2005515779A (ja) * 2002-01-31 2005-06-02 ワイス アグレカナーゼ分子
AU2003222103A1 (en) 2002-03-28 2003-10-13 Idec Pharmaceuticals Corporation Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
WO2005007090A2 (en) 2003-07-03 2005-01-27 President And Fellows Of Harvard College Inhibitors of the map kinase pathway
WO2006031221A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
JP2006302684A (ja) 2005-04-21 2006-11-02 D D K Ltd カードコネクタ
EP2295570A1 (en) * 2005-07-27 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
CN101287831B (zh) 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
US20070099251A1 (en) * 2005-10-17 2007-05-03 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
TWM336439U (en) * 2008-02-14 2008-07-11 Optivision Technology Inc Diffuser capable of light condensing
EP2362904B1 (en) * 2008-08-28 2016-11-16 Oncotherapy Science, Inc. Method of screening compounds for use in inhibiting depdc1 - znf224 binding
KR102015648B1 (ko) 2011-08-12 2019-08-28 온코세라피 사이언스 가부시키가이샤 Ｍｐｈｏｓｐｈ１ 펩티드 및 이를 포함한 백신

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003040165A2 (en) * 2000-10-19 2003-05-15 Epimmune Inc. Hla class i and ii binding peptides and their uses
WO2002046416A2 (en) * 2000-12-04 2002-06-13 Argonex Pharmaceuticals Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2006085684A2 (en) * 2005-02-10 2006-08-17 Oncotherapy Science, Inc. Method of diagnosing bladder cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FERRIES, E. et al. Human Immunology 2001, 62(8), 791-798 *
ITO, K. et al. Int. J. Cancer 2004, 108, 712-724 *

Also Published As

Publication number Publication date
AU2007311395A1 (en) 2008-04-24
CN101568550B (zh) 2012-12-26
KR101493773B1 (ko) 2015-03-03
HK1171024A1 (en) 2013-03-15
KR101527473B1 (ko) 2015-06-17
US20130129759A1 (en) 2013-05-23
KR20090083378A (ko) 2009-08-03
EP2687541A1 (en) 2014-01-22
EP2476699A3 (en) 2013-11-27
EP2476699A2 (en) 2012-07-18
IL198186A0 (en) 2011-08-01
SG175566A1 (en) 2011-11-28
EP2687540A1 (en) 2014-01-22
CN102850434B (zh) 2016-04-13
JP2010506826A (ja) 2010-03-04
US8653234B2 (en) 2014-02-18
ES2545457T3 (es) 2015-09-11
KR20140057681A (ko) 2014-05-13
IL198186A (en) 2017-05-29
EP2476697A3 (en) 2013-11-27
US8557955B2 (en) 2013-10-15
EP2695895A1 (en) 2014-02-12
CA2915560A1 (en) 2008-04-24
SG10201502098YA (en) 2015-05-28
CN102850434A (zh) 2013-01-02
US20120282286A1 (en) 2012-11-08
IL216712A0 (en) 2012-01-31
ES2545818T3 (es) 2015-09-16
US20100028373A1 (en) 2010-02-04
CA2667030C (en) 2016-03-15
EP2091965A4 (en) 2011-02-16
KR101454287B1 (ko) 2014-11-04
EP2476697B1 (en) 2015-06-17
EP2476698B1 (en) 2015-06-17
CN102850433B (zh) 2016-03-02
US20120288514A1 (en) 2012-11-15
WO2008047473A1 (en) 2008-04-24
CA2667030A1 (en) 2008-04-24
EP2476697A2 (en) 2012-07-18
JP2013116115A (ja) 2013-06-13
CN102850435B (zh) 2016-02-17
EP2091965A1 (en) 2009-08-26
EP2091965B9 (en) 2013-09-25
CN101568550A (zh) 2009-10-28
EP2476698A3 (en) 2013-11-27
ES2415958T3 (es) 2013-07-29
EP2476699B1 (en) 2015-06-17
US9017688B2 (en) 2015-04-28
KR20140104057A (ko) 2014-08-27
RU2469044C2 (ru) 2012-12-10
US9545437B2 (en) 2017-01-17
US20150231222A1 (en) 2015-08-20
CN105693843A (zh) 2016-06-22
IL216713A0 (en) 2012-01-31
KR101543622B1 (ko) 2015-08-11
BRPI0717651A2 (pt) 2013-12-24
IL216712A (en) 2017-07-31
PL2091965T3 (pl) 2013-10-31
DK2091965T3 (da) 2013-08-05
EP2476698A2 (en) 2012-07-18
KR20150015042A (ko) 2015-02-09
HK1131169A1 (en) 2010-01-15
RU2009118432A (ru) 2010-11-27
JP5339292B2 (ja) 2013-11-13
HK1171026A1 (en) 2013-03-15
CN102850433A (zh) 2013-01-02
US8552146B2 (en) 2013-10-08
IL222925A0 (en) 2012-12-31
CN102850435A (zh) 2013-01-02
ES2545817T3 (es) 2015-09-16
MX2009004147A (es) 2009-06-15
HK1171025A1 (en) 2013-03-15
PT2091965E (pt) 2013-06-11
EP2091965B1 (en) 2013-05-15

Similar Documents

Publication Publication Date Title
US9545437B2 (en) Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
AU2008218463A2 (en) Peptide vaccines for cancers expressing tumor-associated antigens
AU2012261723A1 (en) Peptide vaccines for cancers expressing tumor-associated antigens
AU2013200566B2 (en) Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
HK1191030A (en) Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides
HK1171026B (en) Peptide vaccines for cancers expressing depdc1 polypeptides
HK1131169B (en) Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides
HK1191019A (en) Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides
HK1190419A (en) Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides
HK1171024B (en) Peptide vaccines for cancers expressing mphosph1 polypeptides
HK1171025B (en) Peptide vaccines for cancers expressing depdc1 polypeptides

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired